Rayocomp PS 1000 polar

High efficiency bio resonator

CASE STUDIES ACCORDING TO DR. MED. GERHARD BREIER COLOGNE

RAYONEX Schwingungstechnik GmbH Sauerland-Pyramiden 1 D-57368 Lennestadt Phone: +49 2721/6006-0 Fax: +49 2721/6006-66

Case study on the RAYOCOMP PS 1000

Dr. med. Gerhard Breier, Cologne, October 1993

In an examination- and study-programme the RAYOCOMP PS 1000 was incorporated with the question, if subtle oscillation therapy methods using resonance frequencies have a healing impact on pathological changes. For this reason the following sectors with indications and case numbers were included in the therapeutical concept:
( N = number of patients)

Dermatology N = 35 Neurodermatitis Allergic eczema Acne Orthopedics N = 215 Coxarthrosis Lumbalgia Spondylarthrocace Occipital-Neuralgia Migraine Ischialgia Cervical spine syndrome Distorsion of ankle joint Cancer (NPL) N=2 Osteosarcoma Alveolar-pavement ephitelium

N= 20 N = 10 N= 5

N = 30 N = 40 N = 20 N = 30 N = 20 N = 30 N = 40 N= 5

N= 1 N= 1

(Only the serological immune profile was examined in the after-treatment) Neurology N=3 Amyotrophic lateral sclerosis (ASL) Extrapyramidal syndrome (EPS) Guillain-Barre-syndrome (GBS) Urology Cystitis Pyelitis N = 20 N = 15 N= 5

N= 1 N= 1 N= 1

HNO N = 31 Sinusitis. Traumatic laryngitis Bacterial laryngitis Otitis media Rheumatology N = 21 Chronic polyarthritis cP. Chronic arthrosis

N = 20 N= 1 N= 5 N= 5

N= 8 N = 13

Circulatory disturbance N = 27 Coronary heart diseases CHD AVK IIb Ulcus venosum Cerebral circulatory disturbance Psychiatry N = 42 Depression, generally Phobia, generally Disturbed sleep, generally Gastro-enterology Gastritis Obstipation Acute diarrhea Colitis ulcerosa N = 56

N= 5 N= 2 N= 5 N = 15

N = 12 N = 10 N = 20

N = 20 N = 20 N= 4 N = 12

Ophthalmology N = 10 Retinal circulatory disturbance Degenerative process of the macula Pulmology N = 52 Bronchial asthma Allergic asthma Rhinitis allergica

N= 8 N= 2

N = 20 N = 10 N = 22

Altogether 514 patients were treated during this case study. Every patient had been informed about the effects of the Rayocomp. Some patients were intentionally given incomplete information to maintain the characteristics of a blind experiment. Side effects or intolerabilities did not occur in any of the cases. None of the treatments had to be cancelled. Between the sessions the patients were given an oral drug on a neutral carrier*1) containing the same bio-resonance frequencies as the treatment. This led usually to a stabilization of the therapeutical result. Interestingly enough an improvement of the state of illness was also ascertainable if the patients were only given the drug and not treated with frequencies. The daily dose varied from 1 x 5 drops to 2 x 10 drops. Overdoses almost regularly led to overreactions including symptoms of hyperactivity. The therapy was performed with therapy cards or an indicated, unsorted combination of cards with up to 480 frequencies. The treatment took place two times a week with normally 12 applications. Only in case of artrioventricular disease the therapy had to be cancelled because of increasing pain, but not until after the 18th application, therefore out of the assesment. In the beginning the treatment was performed with indicated cards, respectively only one card. *1) A radionic drug is a stimulans, consisting only of energetic potentials and not of material pharmacological
substances.

Therapeutical results (Part 1)

Dr. med. Breier, Cologne, October 1993 Deterioration Recuperation

Placebo first reaction small success

% 90

80

70

60

50

40

30

20

10 -

+ 10

20

30

40

50

60

70

80

90 %

Neurodermatitis Allergic eczema Acne Coxarthrosis Lumbalgia Spondylarthrocace Occipital neuralgia Migraine Ischialgia Distorsion of ankle joint Cervical spine syndrome Speech Swallowing Pyramidalsyndrome GBS Cystitis Pyelitis Frontal sinusitis Traumatic laryngitis Bacterial laryngitis

Therapeutical results (Part 2)

Dr. med. Breier, Cologne, October 1993 Deterioration Recuperation

Placebo first reaction small success

% 90

80

70

60

50

40

30

20

10 -

+ 10

20

30

40

50

60

70

80

90 %

Otitis - media Angina Chronic polarthritis Chronic arthrosis CHD AVD Ulcus venosum Cerebral circulatory disturbance Depressions Phobia Disturbed sleep Gastritis Obstipation Diarrhea Colitis ulcerosa Retinale circulatory disturbance Degeneration of the macula Bronchial asthma Allergic asthma Rhinititis allergica

% 90 80
Recuperation

Neurodermatitis

70 60 50 40 30
small success

Acne

Allergic eczema

20 10 + 1 10 20 30 40
Neurodermatitis, therapy cards: 51 - 5 - 7. Additionally from 5th treatment on 15 - 17- 31 - 32 - 34. Acne, therapy cards: 51 - 5 - 7- 32. Additionally from 5th treatment on 29 - 34 - 14 - 15. Allergic eczema, therapy cards: 51 - 5 - 7 -15 -17. Additionally from 5th treatment on 29 -14 - 32 - 34.

Placebo

First reaction

Days

10

Deterioration

50 60 70 80 90 %

Course of treatment (Table 1)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Occipital-Neuralgia

Spondylarthrocace

70 60 50 40 30
small success

Lumbalgia

Coxarthrosis

20 10 + 1 10 20 30 40
Occipital-Neuralgia, therapy cards: 51 - 47 - 48. Additionally from 4th treatment on 1 - 13 - 21 - 46. Spondylarthrocace, therapy cards: 51 - 36 - 50. Additionally from 3rd treatment on 46 - 21 -13 - 2. Lumbalgia, therapy cards: 51 - 36 - 44 - 37. Additionally from 7th treatment on 21 - 50 - 48 - 13.

Placebo

First reaction

Days

10

Deterioration

50 60 70 80 90 %

Coxarthrosis, therapy cards: 51 - 44 - 37 - 46. Additionally from 7th treatment on 50 - 15 - 5.

Course of treatment (Table 2)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Migraine

Cervical spine syndrome

Ischialgia

70 60 50 40 30
small success

20 10 + 1 10 20 30 40
Migraine, therapy cards: 51 - 48 - 50 - 47. Additionally from 3rd trearment on 2 - 13 - 21 - 26 or 27 - 2 - 3 - 8. Cervical spine syndrome, therapy cards: 51 - 46 - 47 - 48. Additionally from 3rd trearment on 41 - 50 - 36.

Distorsion of the ankle joint

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Ischialgia, therapy cards: 51 - 36 - 50 - 21. Additionally from 5th trearment on 13 - 44 - 37 - 46. Distorsion of the ankle joint, therapy cards: 38 -37. Additionally from 7th trearment on 44 - 2 -3.

Course of treatment (Table 3)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Cystitis

70 60 50 40 30
small success

Pyelitis

20 10 + 1 10 20 30 40
Cystitis, therapy cards: 28 - 34. Additionally from 6th treatment on 5 - 14 - 26 or 27. Pyelitis, therapy cards: : 34 - 28. Additionally from 7th treatment on 26 or 27 - 14 - 2 - 3 - 17 - 15

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Course of treatment (Table 4)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Chronic polyarthritis

chronic arthrosis

70 60 50 40 30
small success

20 10 + 1 10 20 30 40
Chronic polyarthritis cP., therapy cards: 51 - 50 - 34 - 21. Additionally from 5th treatment on 43 - 42 - 45 - 44 - 37. Additionally from 7th treatment on 5 - 15 - 17 - 34 - 31 - 30 - 32 - 20. Chronic arthrosis, therapy cards: 51 - 45 - 37 - 34. Additionally from 5th treatment on 15 - 17 - 36 - 21 - 5.

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Course of treatment (Table 5)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

70 60 50 40 30
small success

Retinal circulatory disturbance

20 10 + 1 10 20 30 40
Retinal circulatory disturbance, therapy cards: 51 - 11 - 5. Additionally from 3rd treatment on 3 - 4 - 12 - 14. Degenerative process of the macula, therapy cards same combination as above.

Degenerative process of the macula

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Course of treatment (Table 6)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

70 60 50 40 30
small success

Disturbed sleep

Depressions

20 10 + 1 10 20 30 40

Phobia

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %
Disturbed sleep, therapy cards: 51 - 12 - 13. Additionally after 1st treatment 20 - 21. Additionally from 5th treatment on 11 - 1 - 50 - 15 - 14 - 23. Depressions, therapy cards: 51 - 1 - 12 - 13. Additionally after 3rd treatment 50 - 20. Additionally after 4th treatment 26 oder 27 - 3 - 4 - 2. Phobia, therapy cards: same combination as with depressions

Course of treatment (Table 7)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Allergis asthma

Bronchial

asthma Rhinititis allergica

70 60 50 40 30
small success

20 10 + 1 10 20 30 40
Allergic asthma, therapy cards: 51 - 19. Additionally from 2nd treatment on 10 - 20. Additionally from 4th treatment on12 - 15 - 17 - 32 - 34. Bronchial asthma, therapy cards: 51 -19. Additionally after 1st treatment 20 - 34 - 12. Additionally after 5th treatment 10 - 17 - 32. Additionally after 6th treatment 46 - 23 - 39 - 35. Additionally after 8th treatment 16 - 30.

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Rhinititis allergica, therapy cards: 51 - 10. Additionally from 2nd treatment on 13 - 14. Additionally from 6th treatment onh 20 - 34 - 15 -17 - 19.

Course of treatment (Table 8)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

70 60 50 40 30
small success

Coronary

heart diseases

Ulcus venosum

Cerebral circulatory disturbance

20 10 + 1 10 20 30 40

Placebo

first reaction

Days

10

AVK II b

Deterioration

50 60 70 80 90 %
CHD, therapy cards: 51 - 35 - 3 - 4. Additionally from 5th treatment on 39 - 46 Additionally from 7th treatment on 23 - 16 - 30 - 32 - 50 Ulcus venosum, therapy cards: 3 - 14 -15 -17 - 34. Additionally from 2nd treatment on 5 - 7 - 14 - 45. Cerebral circ. disturb., therapy cards: 51 - 1 - 3 - 4 - 8 - 12. Additionally from 4th treatment on 13 - 48 - 47. AVK, therapy cards: 3 - 4 - 44. Additionally from 4th treatment on 14 - 15. Additionally from 7th treatment on 35 - 5.

Course of treatment (Table 9)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Gastritis

Diarrhea

70 60 50 40 30
small success

Obstipation

Colitis ulcerosa

20 10 + 1 10 20 30 40
Gastritis, therapy cards: 51 - 29. Additionally from 2nd treatment on 30 - 31. Additionally from 5th treatment on 23 - 18 - 2. Diarrhea, therapy cards: 51 - 32. Additionally from 2nd treatment on 31 - 30 - 29 - 16 - 5 - 17.

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Obstipation, therapy cards: 51 - 32. Additionally from 3rd treatment on33 - 31 - 30. Additionally from 5th treatment on 15 - 17 - 50. Colitis ulcerosa, therapy cards: 51 - 32. Additionally after 3rd treatment 31 - 30. Additionally after 5th treatment 5 - 2 - 16. Additionally after 9th treatment 14 - 15.

Course of treatment (Table 10)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

Angina

Bact. laryngitis Sinusitis Traum. laryngitis after intubation

70 60 50 40 30
small success

Otitis media

20 10 + 1 10 20 30 40
Angina, therapy cards: 51 - 14. Additionally after 1st treatment 9 - 10 - 47 - 15 - 17 - 34 - 5. Laryngitis, therapy cards: 9 - 14. Additionally after 3rd treatment 5 - 3 - 4 - 15. Otitis media, therapy cards: 51 - 8. Additionally after 4th treatment 14 - 10 - 13 - 3 - 4 - 48.

Placebo

first reaction

Days

10

Deterioration

50 60 70 80 90 %

Course of treatment (Table 11)

Dr. med. Breier, Cologne, October 1993

Immune status before and after the Rayocomp treatment (Table 1)

Dr. med. Breier, Cologne, October 1993

5000 4,8 Evy 4,3 233 Leucocytes 41 HK 37

52

Chol. 181 37

HDL

142

LDL 125 83 Triyl. 84

Lipase 2300 66

41

before

after

Immune status before and after the Rayocomp treatment (Table 2)

Dr. med. Breier, Cologne, October 1993

130

1140 110 110

Lymphocytes 850

Active T-cells

NK-cells

70 245000 Throbocyres 650 201000 530 350 3,4 Monocytes 220 Granulocytes 2,9 30 240 T4 T8 330 550 T-Ly B-Ly 70

60

470

cytic T-cells

30

before

after

Here the subpopulation of lymphocytes before and after 10 treatments with the Rayocomp was measured. With ephitelioma after lopektomie recurrenct. General condition very good. No postoperative pain, vital capacity. NAD. Of special meaning is the increase of T4 cells from 330 to 550 and of T8 cells from 240 to 470, and the immune competent NK-cells increase from 60 to 130 and the cytotoxic cells, that are important for the specific immune response, from 30 to 70. This small amount of case numbers is only useful for observation. There are further CA.-patients in the therapy, but still without measurable results.

% 90
10% 20% 30%

80
Recuperation

70 60 50 40 30
small success
15% 20% 50% 25 % 20%

20 10 + 10 20 30 40
Neurodermatitis Allergic Eczema

Placebo first reaction

N = 20

N = 10

Deterioration

50 60 70 80 90 %

Only with 15 % there was little efficiency, with the rest of the population (85%) the treatment was definitely effective.

Initial deterioration followed by slight improvement with 20 % and 70 % within the range of efficiency.

Efficiency with "N" persons examined (Table 1)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation
5% 10% 10% 15% 55% 40%

10% 15%

10%

30% 35%

70
20% 30% 40% 20% 40%

15%

60%

60 50 40 30
small success
20% 10% 20%

20 10 + 10 20 30 40
Coxartthr. Lumbalgia Spondylarthr.

Placebo first reaction

N = 30

N = 40

N = 40

Occipital - Neuralgia

Migraine

N = 30

N = 20
With 10% recurrence over years, also postoperative with pain and restricted mobility. Regarding the severity of the disease success in small groups, but nevertheless definite.

Deterioration

50 60 70 80 90 %

20% are so strongly degenerated and modified in their anatomic structure, that recuperation is impossible.

Often combined with Occipital-Neuralgia and migraine with definite therapeutical lumbalgie and Ischiasneuralgia success. and degenerative, effect thinkable over tendinous structures and with remarkable success.

Efficiency with "N" persons examined (Table 2)

Dr. med. Breier, Cologne, October 1993

% 90
30% 25% 45% 10%

80
10%

Recuperation

70 60 50 40
30% 40% 10%

40% 60%

30% 20% 40%

20%

30
small success

45%

20 10 +
10%

Placebo

15%

first reaction

10 20 30 40
Ischialgia Cervical spine syndrome Ankle joint distorsion

N = 30
30% chronically recurrent, but good success in small groups.

N = 40

N=5
Hardly any success with the increase of mobility, but a reduction of pain and oedemas.

ASL Speech

ASL Swallowing

N =1

N=1

With around 50% slight improvement of speech, but not stable, better with swallowing. the disease is in progress, the patients very unstable.

Deterioration

50 60 70 80 90 %

Efficiency with "N" persons examined (Table 3)

Dr. med. Breier, Cologne, October 1993

% 90
20%

20%

80
Recuperation

10%

70 60
30% 20% 10% 30% 10% 30%

30%

40%

50 40 30
small success
80% 30% 40% 20%

20% 20%

20%

20 10 +
20%

Placebo first reaction

10 20 30 40
Extra pyramidal syndrome*

Cystitis N = 15

Deterioration

50 60 70 80 90 %

Pyelitis N = 5

Sinusitis N = 20

GBS

Depressions

Phobia

Disturbed sleep

N=1
*EPS: Indifferent behavior caused psychich disturbance.

N = 12

N = 10

N = 20

With depressions instable patient structure, efficiency only in a small group of 30 % % relatively stable, otherwise short efficiency and recurrent, similar to phobia.

Efficiency with "N" persons examined (Table 4)

Dr. med. Breier, Cologne, October 1993

% 90
15% 15% 30% 20% 20% 20% 25%

20%

80
Recuperation

70 60 50 40 30
small success
40% 20% 20% 15% 15% 20%

15%

40% 10%

30%

20 10 +
10%

Placebo first reaction

10 20 30 40

Deterioration

50 60 70 80 90 %

Traumatic laryngitis

Bacterial laryg.

Otitis media

Angina

N=1

N=5

N=5

N=2

Otitis media and angina comparable form and definite efficiency without recurrence.

Efficiency with "N" persons examined (Table 5)

Dr. med. Breier, Cologne, October 1993

% 90
10% 10%

80
Recuperation

15% 10% 10% 15% 10% 20% 30% 20% 40%

70 60 50 40 30
small success
15% 20% 60% 30%

20 10 + 10 20 30 40
Chron. polyarthritis Chron. Arthr.
20% 25% 30% 10%

Placebo first reaction

AVK II b

CHD

N=8
Strong degeneration of the fingers with restricted mobility and pain. About ca. 40% with small or no effect. 35 % with moderate effect, slightly improved mobility and reduced pain. No recurrence. Duration of efficiency relatively stable. 25% with exellent and stable effect. No recurrence up to end of Nov. 93.

N = 13

N=2

N=5

Deterioration

50 60 70 80 90 %

Often coronary insufficiency with decompensated geriatric heart; inspite definite symptomatic improvement and reduction of the dyspnoe.

Efficiency with "N" persons examined (Table 6)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

20%

70 60 50 40 30
small success
30% 20%20% 20% 30% 30% 20% 30%

20%

30%

20%

10%

20 10 +
10%

40% 30%

20% 20%

30%

Placebo

25% 25%

first reaction

10 20 30 40
Ulcus venosum Cerebral circ. disturb. Depressions Phobia

Disturbed sleep

N=5
Chronic system diseases with repeated recurrence, 30% indifferent, 20% slight occusion of the ulcus but no total healing, 50 % with satisfying closure, no recurrence.

N = 15
Vascular degeneration, only in 20 % of the cases slight symptomatic improvement possible.

N = 12

N = 10

N = 20

Deterioration

50 60 70 80 90 %

Efficiency with "N" persons examined (Table 7)

Dr. med. Breier, Cologne, October 1993

% 90
20%

80
Recuperation

70
20%

30% 30% 20%

10%

60 50
20% 20% 30% 20% 30% 20%

30%

40 30
small success

30% 20%

20 10 + 10 20 30 40

20% 30%

Placebo first reaction

Deterioration

50 60 70 80 90 %

Gastritis

Obstipation

Diarrhoe

Colitis ulzerosa

N = 20

N = 20

N=4

N = 12

Efficiency with "N" persons examined (Table 8)

Dr. med. Breier, Cologne, October 1993

% 90 80
Recuperation

10% 10%

70 60 50
30% 20% 10%

30%

20%

40% 30%

20%

40 30
small success
35% 35% 40% 40% 20%

30%

30%

30%

20%

20 10 + 10 20 30 40
Retinal circ. dist. Deg. of the macula bronchial asthma

Placebo first reaction

Allgic asthma

Allergic Rhinitis

N=8
In 30% of the cxases lasting improvement of the vision (eye charts, shortand longsighted)

N=2

Deterioration

50 60 70 80 90 %

30% destruction of the respiratory passages, degenerative, only slight symptomatic improvement. 50 % with slight or good improvement also of the vital capacity. 40% with clear symptomatic improvement also of the vital capacity.

N = 20

N = 10

N = 22

A llergic rhinitis depends on allegies and seasons. 20 % without clear effect. 30 % variable for the same reasons. Rest of the population with definite success without recurrence.

Efficiency with "N" persons examined (Table 9)

Dr. med. Breier, Cologne, October 1993